251 related articles for article (PubMed ID: 31465522)
1. Longitudinal follow up of serological response in children treated for Chagas disease.
Moscatelli G; Moroni S; García Bournissen F; González N; Ballering G; Schijman A; Corral R; Bisio M; Freilij H; Altcheh J
PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007668. PubMed ID: 31465522
[TBL] [Abstract][Full Text] [Related]
2. Prediction of parasitological cure in children infected with Trypanosoma cruzi using a novel multiplex serological approach: an observational, retrospective cohort study.
Jurado Medina L; Chassaing E; Ballering G; Gonzalez N; Marqué L; Liehl P; Pottel H; de Boer J; Chatelain E; Zrein M; Altcheh J
Lancet Infect Dis; 2021 Aug; 21(8):1141-1150. PubMed ID: 33836157
[TBL] [Abstract][Full Text] [Related]
3. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
[TBL] [Abstract][Full Text] [Related]
4. Benznidazole treatment in chronic children infected with Trypanosoma cruzi: serological and molecular follow-up of patients and identification of Discrete Typing Units.
Rumi MM; Pérez Brandán C; Gil JF; D'Amato AM; Ragone PG; Lauthier JJ; Tomasini N; Cimino RO; Orellana V; Lacunza CD; Nasser JR; Basombrío MA; Diosque P
Acta Trop; 2013 Oct; 128(1):130-6. PubMed ID: 23880286
[TBL] [Abstract][Full Text] [Related]
5. Posttherapeutic cure criteria in Chagas' disease: conventional serology followed by supplementary serological, parasitological, and molecular tests.
Machado-de-Assis GF; Silva AR; Do Bem VA; Bahia MT; Martins-Filho OA; Dias JC; Albajar-Viñas P; Torres RM; Lana M
Clin Vaccine Immunol; 2012 Aug; 19(8):1283-91. PubMed ID: 22739694
[TBL] [Abstract][Full Text] [Related]
6. Persistence of PCR-positive tissue in benznidazole-treated mice with negative blood parasitological and serological tests in dual infections with Trypanosoma cruzi stocks from different genotypes.
Martins HR; Figueiredo LM; Valamiel-Silva JC; Carneiro CM; Machado-Coelho GL; Vitelli-Avelar DM; Bahia MT; Martins-Filho OA; Macedo AM; Lana M
J Antimicrob Chemother; 2008 Jun; 61(6):1319-27. PubMed ID: 18343804
[TBL] [Abstract][Full Text] [Related]
7. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.
de Andrade AL; Zicker F; de Oliveira RM; Almeida Silva S; Luquetti A; Travassos LR; Almeida IC; de Andrade SS; de Andrade JG; Martelli CM
Lancet; 1996 Nov; 348(9039):1407-13. PubMed ID: 8937280
[TBL] [Abstract][Full Text] [Related]
8. The Trypomastigote Small Surface Antigen from Trypanosoma cruzi Improves Treatment Evaluation and Diagnosis in Pediatric Chagas Disease.
Balouz V; Melli LJ; Volcovich R; Moscatelli G; Moroni S; González N; Ballering G; Bisio M; Ciocchini AE; Buscaglia CA; Altcheh J
J Clin Microbiol; 2017 Dec; 55(12):3444-3453. PubMed ID: 28978686
[TBL] [Abstract][Full Text] [Related]
9. A novel antibody surrogate biomarker to monitor parasite persistence in Trypanosoma cruzi-infected patients.
Zrein M; Granjon E; Gueyffier L; Caillaudeau J; Liehl P; Pottel H; Cardoso CS; Oliveira CDL; de Oliveira LC; Lee TH; Ferreira AM; Ribeiro ALP; Busch MP; Sabino EC
PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006226. PubMed ID: 29425201
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the ELISA-F29 test as an early marker of therapeutic efficacy in adults with chronic Chagas disease.
Fabbro D; Velazquez E; Bizai ML; Denner S; Olivera V; Arias E; Pravia C; Ruiz AM
Rev Inst Med Trop Sao Paulo; 2013; 55(3):. PubMed ID: 23740013
[TBL] [Abstract][Full Text] [Related]
11. Antibody drop in newborns congenitally infected by Trypanosoma cruzi treated with benznidazole.
Chippaux JP; Clavijo AN; Santalla JA; Postigo JR; Schneider D; Brutus L
Trop Med Int Health; 2010 Jan; 15(1):87-93. PubMed ID: 19968839
[TBL] [Abstract][Full Text] [Related]
12. Assessing antibody decline after chemotherapy of early chronic Chagas disease patients.
Murphy N; Cardinal MV; Bhattacharyya T; Enriquez GF; Macchiaverna NP; Alvedro A; Freilij H; Martinez de Salazar P; Molina I; Mertens P; Gilleman Q; Gürtler RE; Miles MA
Parasit Vectors; 2021 Oct; 14(1):543. PubMed ID: 34670602
[TBL] [Abstract][Full Text] [Related]
13. Use of an enzyme-linked immunosorbent assay that utilizes the Tc13Tul antigen of Trypanosoma cruzi to monitor patients after treatment with benznidazole.
Santamaría AL; De Rissio AM; Riarte A; Garavaglia PA; Bruballa AC; Rodríguez MA; Irazu LE; Ruiz AM; García GA
Diagn Microbiol Infect Dis; 2013 Jun; 76(2):197-205. PubMed ID: 23537784
[TBL] [Abstract][Full Text] [Related]
14. Serological profiles and evaluation of parasitaemia by PCR and blood culture in individuals chronically infected by Trypanosoma cruzi treated with benzonidazole.
Aguiar C; Batista AM; Pavan TB; Almeida EA; Guariento ME; Wanderley JS; Costa SC
Trop Med Int Health; 2012 Mar; 17(3):368-73. PubMed ID: 22212647
[TBL] [Abstract][Full Text] [Related]
15. An α-Gal antigenic surrogate as a biomarker of treatment evaluation in Trypanosoma cruzi-infected children. A retrospective cohort study.
Abal M; Balouz V; Lopez R; Giorgi ME; Marino C; Cruz CV; Altcheh J; Buscaglia CA
PLoS Negl Trop Dis; 2024 Jan; 18(1):e0011910. PubMed ID: 38236916
[TBL] [Abstract][Full Text] [Related]
16. Treatment Success in Trypanosoma cruzi Infection Is Predicted by Early Changes in Serially Monitored Parasite-Specific T and B Cell Responses.
Alvarez MG; Bertocchi GL; Cooley G; Albareda MC; Viotti R; Perez-Mazliah DE; Lococo B; Castro Eiro M; Laucella SA; Tarleton RL
PLoS Negl Trop Dis; 2016 Apr; 10(4):e0004657. PubMed ID: 27128444
[TBL] [Abstract][Full Text] [Related]
17. Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease.
Viotti R; Vigliano C; Alvarez MG; Lococo B; Petti M; Bertocchi G; Armenti A; De Rissio AM; Cooley G; Tarleton R; Laucella S
PLoS Negl Trop Dis; 2011 Sep; 5(9):e1314. PubMed ID: 21909451
[TBL] [Abstract][Full Text] [Related]
18. [Anti-F2/3 antibodies as cure marker in children with congenital Trypanosoma cruzi infection].
Altcheh J; Corral R; Biancardi MA; Freilij H
Medicina (B Aires); 2003; 63(1):37-40. PubMed ID: 12673959
[TBL] [Abstract][Full Text] [Related]
19. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial.
Torrico F; Gascon J; Ortiz L; Alonso-Vega C; Pinazo MJ; Schijman A; Almeida IC; Alves F; Strub-Wourgaft N; Ribeiro I;
Lancet Infect Dis; 2018 Apr; 18(4):419-430. PubMed ID: 29352704
[TBL] [Abstract][Full Text] [Related]
20. Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras.
Escribà JM; Ponce E; Romero Ade D; Viñas PA; Marchiol A; Bassets G; Palma PP; Lima MA; Zúniga C; Ponce C
Mem Inst Oswaldo Cruz; 2009 Nov; 104(7):986-91. PubMed ID: 20027465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
